Navigation Links
A novel prognostic marker for biliary atresia
Date:3/8/2011

Biliary atresia (BA) is an inflammatory obliterative cholangiopathy with unknown etiology, leading to progressive fibrosis and cirrhosis. Microarray technology, emerged as an indispensable research tool for gene expression profiling, has been used to study the mechanism underlying BA, and allows the simultaneous analysis of thousands of transcripts within a single experiment. Some studies have been performed to investigate the gene expression profiling of livers from BA patients. However, none of them was designed to identify genes that play a key role in the pathogenesis and prognosis of BA.

A research article to be published on February 14, 2011 in the World Journal of Gastroenterology addresses this question. In this study, DNA microarrays for whole genome gene expression and bioinformatics analysis were used to characterize the differentially expressed gene patterns of normal livers and livers from BA patients at different ages, as well as to ascertain the genes and pathways that play a central role in the pathogenesis of BA. Furthermore, reverse-transcription polymerase chain reaction was performed to confirm the changes in selected genes. The relation between selected gene expression and prognosis of BA patients was also analyzed.

The results showed autoimmune response mediated by T lymphocytes may play a vital role in the pathogenesis of BA. The RRAS gene and its related MAPK pathway are important regulatory modules in the pathogenesis of BA, which may serve as a novel prognostic marker for BA.

By identifying genes and pathways playing a central role in the pathogenesis of BA, this study may represent a future strategy for therapeutic intervention in treatment of BA.


'/>"/>

Contact: Ye-Ru Wang
wjg@wjgnet.com
86-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Page: 1

Related medicine news :

1. Genome sequencing used to assess a novel form of Clostridium botulinum
2. Novel mechanism for control of gene expression revealed
3. Novel methods for improved breast cancer survival
4. Novel immune system-based gene therapy induces strong responses in metastatic melanoma, sarcoma
5. Novel surgery removes rare tumor, rebuilds trachea
6. Researchers reveal function of novel molecule that underlies human deafness
7. Novel therapy for metastatic kidney cancer developed at VCU Massey Cancer Center
8. UCI researchers find novel memory-enhancing mechanism in brain
9. Novel imaging technique may reduce lymphedema in breast cancer patients
10. New standards of care and novel treatment options for several forms of lymphoma unveiled
11. Novel genetic mutation that causes the most common form of eye cancer discovered
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... New York, NY (PRWEB) , ... May 27, ... ... health care world, this installment is bolstered by inspiring human interest stories, courtesy ... to the developing trends and tech within the industry, from leading advocates and ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... ... trusted name in the pharmaceutical, medical and food industries. Aside from its GMP ... certification (SIC), providing proof of successfully certified products, services and staff. , Validation ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... W.S. ... products, has been honored with a 2016 When Work Works Award for its use ... part of the national When Work Works project administered by the Families and Work ...
(Date:5/26/2016)... ... 2016 , ... Georgia State University College of Law is ... Answering to the increasing demand for curricular specializations, the Certificate in Intellectual Property ... land use law. ,  , “The demand for lawyers with specific knowledge in ...
(Date:5/26/2016)... , ... May 26, 2016 , ... The Woodlands ... offering a new model of care for living and healing, celebrated its grand ... Meaningful Life in a Real Home provided by Empowered Staff. , “This is an ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... Celsion Corporation (NASDAQ: CLSN ... an update on its ongoing OVATION study, a ... the Company,s DNA-based immunotherapy, with the standard of ... advanced ovarian cancer who will undergo neoadjuvant chemotherapy ... IL-12 DNA plasmid vector formulated as a nanoparticle ...
(Date:5/24/2016)... , May 24, 2016 ... the world , s first dual therapy ... intervention   OrbusNeich, a global company specializing ... its portfolio to include products to treat peripheral artery ... company,s first entry devices for lower limb and arteriovenous ...
(Date:5/24/2016)... HONG KONG , May 24, 2016 ... de COMBO ™ , la ... présentent des cathéters destinés à l,intervention portant ... artério-veineuse (FAV)   OrbusNeich, entreprise ... vasculaires permettant de changer la vie, a ...
Breaking Medicine Technology: